Hematological Oncology

Papers
(The TQCC of Hematological Oncology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma48
Competitive evolved sub‐clonal BCR::ABL1 and novel MSI2::PC fusion genes in myelodysplastic syndrome with isolated del(5q)43
Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases38
Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective study29
CC‐99282 plus R‐CHOP in patients (pts) with previously untreated aggressive B‐cell lymphoma (a‐BCL): early safety and efficacy results from a phase 1b study26
SUBCLONAL HETEROGENEITY DRIVING PROGRESSION AND TRANSFORMATION IN CHRONIC LYMPHOCYTIC LEUKEMIA25
REAL‐WORLD DURATION OF VENETOCLAX TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA22
PHASE 1 TRIAL OF KT‐413, A DEGRADER OF IRAK4 AND IMID SUBSTRATES, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMAS21
Response‐adapted mosunetuzumab for untreated follicular and marginal zone lymphomas: significant monotherapy activity seen in results of an interim efficacy analysis20
Autologous and allogeneic stem‐cell transplantation for transformed Waldenström macroglobulinemia20
Regulatory approvals and survival benefit for novel lymphoma drugs from 2013–202220
Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T‐cell Lymphoma (PTCL): Early trial analysis18
Impact of COVID‐19 infection on bispecific antibodies treatment in patients diagnosed with B‐cell lymphoproliferative disorders18
Health‐related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso‐cel in TRANSCEND CLL 00418
BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient‐Derived Models17
AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (R/R) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDY17
NOTCH PATHWAY MUTATION CONTRIBUTES TO INFERIOR PROGNOSIS IN HBV‐INFECTED CHRONIC LYMPHOCYTIC LEUKEMIA17
T cell CD62L expression following nivolumab therapy is associated with response to rituximab‐nivolumab in treatment naïve follicular lymphoma: the 1st FLOR study17
CLINICAL OUTCOMES BY PROGRESSION OF DISEASE WITHIN 24 MONTHS (POD24) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) TREATED WITH LINPERLISIB17
IMMUNOTHERAPY ALONE VERSUS CHEMOIMMUNOTHERAPY AS FIRST‐LINE TREATMENT OF MARGINAL ZONE LYMPHOMA (MZL): A REAL‐WORLD ANALYSIS17
Impact of PET‐2 guided treatment de‐escalation on time‐to‐recovery from cancer‐related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study16
A MULTI‐CENTER RETROSPECTIVE STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NK/T‐CELL LYMPHOMA16
RADIOTHERAPY BRIDGING IN LARGE B‐CELL LYMPHOMA PATIENTS RECEIVING CD19 CAR‐T – THE UK EXPERIENCE15
A PHASE I STUDY OF SPLIT‐COURSE BRIDGING RADIOTHERAPY (SC‐BRT) PRIOR TO COMMERCIAL CD19 CAR T‐CELL THERAPIES FOR PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL LYMPHOMAS15
CLinicopathological characteristics of extranodal marginal zone B‐cell lymphoma of the intestine: a single center analysis15
RITUXIMAB‐CONTAINING COMBINED MODALITY THERAPY IN LIMITED STAGE FOLLICULAR LYMPHOMA: MATURE FOLLOW UP AND DERIVATION OF A NOVEL PROGNOSTIC SCORE FROM THE TROG99.03 TRIAL14
Safety and Efficacy of Acalabrutinib, Bendamustine, and Rituximab in Patients with Treatment‐Naive or Relapsed/Refractory Mantle Cell Lymphoma: Phase Ib Trial14
MINIMAL RESIDUAL DISEASE STATUS IMPROVED THE RESPONSE EVALUATION IN PATIENTS WITH WALDENSTRöM’S MACROGLOBULINEMIA14
‘Don’t keep me waiting’: estimating the impact on lifetime survival and QALYs of reduced vein‐to‐vein time for LBCL patients treated with CAR T in the 3L+ setting14
PATTERNS OF CIRCULATING NK CELL DYSFUNCTION IN PATIENTS WITH LYMPHOMA14
Matching‐adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)14
Quality of life and response shift effect of diffuse large B‐cell lymphoma French patients included in prospective real‐life REALYSA cohort in the first year after diagnosis14
NEW DRUG DEVELOPMENT IN LYMPHOMA OF CHINA IS GOING GLOBAL13
IMPACT OF TUMOR MUTATIONAL BURDEN ON THE RESPONSE TO IMMUNOCHEMOTHERAPY IN FOLLICULAR LYMPHOMA13
OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)13
VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.12
SOLUBLE MACROPHAGE MARKER SCD163 PREDICTS OUTCOME IN BOTH CHEMOIMMUNOTHERAPY AND TARGETED THERAPY TREATED MANTLE CELL LYMPHOMA12
SINGLE CELL LANDSCAPE OF MULTICENTRIC CASTLEMAN DISEASE IN IDENTICAL TWINS12
Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study12
PHASE 1B OPEN‐LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (LOTIS‐7)12
Genomic Correlates of Radiosensitivity in Diffuse Large B Cell Lymphoma12
IBRUTINIB PLUS BR OR R‐CHOP IN PREVIOUSLY TREATED PATIENTS WITH FOLLICULAR OR MARGINAL ZONE LYMPHOMA: THE PHASE 3 SELENE STUDY12
MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY11
Molecular features possessed in the ctDNA reveal heterogeneity and predict outcome in newly diagnosed peripheral T‐cell lymphoma11
BISPECIFIC ANTI‐CD20/19 CAR‐T—ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL—INTERIM ANALYSIS RESULTS OF DALY‐II‐USA STUDY11
CHARACTERISTICS AND TREATMENT OUTCOMES OF AGGRESSIVE HIGH GRADE B CELL LYMPHOMA WITH MYC AND BCL 6 REARRANGEMENTS11
Combination of the PD‐1 inhibitor Nivolumab and Immunomodulatory Drug Lenalidomide in Relapsed Hodgkin and Large B‐cell Lymphoma: Results from a Phase I/II Study11
Machine Learning‐Based Stem Cell‐Like Phenotype Identification and Novel Risk Stratification in Diffuse Large B‐Cell Lymphoma: Multi‐Omics Data from Multicenter Studies11
EFFECTS OF ALTERNATING MAGNETIC FIELD ON THE EXPRESSION OF ACTIVATION MARKERS CD154 AND CD69 IN JURKAT CELL LINE10
DIVERSITY OF INTRATUMORAL REGULATORY T CELLS IN B‐CELL NON‐HODGKIN LYMPHOMA10
CELL‐FREE DNA KINETICS DECIPHER POTENTIAL MECHANISMS OF ACTION OF IBRUTINIB COMBINATION THERAPY IN MANTLE CELL LYMPHOMA (MCL)10
Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma10
A phase 2 study of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B‐cell malignancies: waveLINE‐00610
A Retrospective Analysis of Clinical Characteristics, Treatment, and Outcomes in Large B‐cell Lymphomas with Synchronous Systemic and Central Nervous System Involvement10
TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)—A COHORT FROM THE ELM‐2 STUDY10
Treatment outcomes of Limited Stage Grade 3A Follicular Lymphoma10
HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R‐CHOP IN PREVIOUSLY UNTREATED (1L) HIGH‐RISK DLBCL, INCLUDING DOUBLE‐HIT/TRIPLE‐HIT: EPCORE NHL‐2 UPDATE9
Prognostic factors of children and adolescents with T‐cell acute lymphoblastic leukemia after allogeneic transplantation9
CHARACTERISTICS OF PATIENTS ACHIEVING COMPLETE OR PARTIAL RESPONSE (CR/PR) WITH TAZEMETOSTAT (TAZ) IN WILD‐TYPE RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)9
BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED CD30‐POSITIVE PERIPHERAL T‐CELL LYMPHOMAS: REAL‐WORLD DATA9
Issue Information9
IMMUNE AND VIRUS‐SPECIFIC RESPONSES IN PARTICIPANTS WITH PRIMARY EFFUSION LYMPHOMA RECEIVING LENALIDOMIDE, DOSE‐ADJUSTED EPOCH, AND RITUXIMAB (EPOCH‐R2)9
EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS9
Study of the efficacy of novel bispecific antibodies targeting immune checkpoints in a 3D model of B non‐Hodgkin lymphoma9
BENDAMUSTINE‐RITUXIMAB COMPARED TO RITUXIMAB‐CHOP/CVP FOR TREATMENT OF PATIENTS WITH INDOLENT LYMPHOMA IN ONTARIO: A POPULATION‐BASED STUDY9
9
PREDICTION OF RELAPSE BY STANDARDIZED IG‐BASED ALLEL‐SPECIFIC QPCR, DDPCR AND AMPLICON NGS FOR MRD MONITORING IN MANTLE CELL LYMPHOMA: A COMPARATIVE ANALYSIS BY THE EU‐MCL NETWORK8
EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MANTLE CELL LYMPHOMA (MCL) IN BELGIAN ROUTINE CLINICAL PRACTICE WITH A 3‐YEAR FOLLOW‐UP8
PRMT5 INHIBITION RESTARTS A PRO‐APOPTOTIC PROGRAM AND CREATES VULNERABILITY TO COMBINATION TREATMENT WITH BCL‐2 INHIBITOR VENETOCLAX IN MANTLE CELL LYMPHOMA8
PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐ A JOINT ANALYSIS OF TWO CLINICAL DATABASES8
PHASE 1 RESULTS OF ANTI‐PD‐LIGAND 1 (DURVALUMAB) & LENALIDOMIDE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA AND CORRELATION WITH GENE EXPRESSION PROFILE8
ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDY8
A NON‐INTERVENTIONAL STUDY OF OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (URBAN): IMPACT OF COVID‐19 PANDEMIC ON ENROLLMENT AND SAFETY8
FAVOURABLE PROGNOSTIC ROLE OF HIGH BASAL MAXIMAL STANDARDIZED UPTAKE VALUE IN FOLLICULAR LYMPHOMA8
OUTCOME DETERMINANTS OF COMMERCIAL CAR‐T CELL THERAPY FOR LARGE B‐CELL LYMPHOMA: RESULTS OF THE GLA/DRST REAL WORLD ANALYSIS8
GLYCOPROTEIN PTGDS ACTS AS A POTENTIAL TARGET IN DIFFUSE LARGE B‐CELL LYMPHOMA BY REGULATING MYH9‐WNT‐β‐CATENIN/STAT3 AXIS8
R‐GDP SCHEDULE IN PATIENTS WITH REFRACTORY OR RELAPSED B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL)8
SARCOPENIA IS AN INDEPENDENT PROGNOSTIC FACTOR IN ELDERLY MALE PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: RESULTS FROM A MULTICENTER EXPERIENCE8
PATIENT‐REPORTED QUALITY OF LIFE (QOL) FOLLOWING TISAGENLECLEUCEL (TISA‐CEL) INFUSION IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)8
INTEGRATION OF BASELINE METABOLIC PARAMETERS AND MUTATIONAL PROFILE PREDICTS OUTCOME IN DLBCL PATIENTS. A POST HOC ANALYSIS OF SAKK38/07 STUDY8
A CONTINUOUS INDIVIDUALIZED RISK INDEX FOR REFINED OUTCOME PREDICTION AFTER TARGETED THERAPY FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CIRI‐CLL)8
THE POTENTIAL EFFICACY AND MECHANISM OF BENDAMUSTINE IN ENTRA‐NODAL NK/T CELL LYMPHOMA8
RITUXIMAB AND NONPEGYLATED LIPOSOMIAL DOXORUBINCIN (R‐NPLD) TREATMENT IN PATIENTS 80 YEARS OF AGE OR OLDER AFFECTED BY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL): A 2020 UPDATE AND IMPLICATIONS OF CLINICAL8
TRACKING CLONAL HEMATOPOIESIS IN PATIENTS WITH CLASSICAL HODGKIN'S LYMPHOMA8
SUBTYPES OF MALIGNANT LYMPHOMAS IN UKRAINE, ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE UKRAINIAN LYMPHOMA REGISTRY8
IRONOMYCIN KILLS DIFFUSE LARGE B‐CELL LYMPHOMA CELLS BY TARGETING CELLULAR IRON HOMEOSTASIS8
AUTOLOGOUS TRANSPLANT IN ELDERLY PATIENTS WITH R/R AGGRESSIVE LYMPHOMA SELECTED BY SIMPLIFIED CGA: THE RECANZ PROSPECTIVE PHASE 2 STUDY BY THE FONDAZIONE ITALIANA LINFOMI8
T‐CELL SUBSET COMPOSITION AND FUNCTIONALITY IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA7
MATURE RESULTS FROM A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN AND DACARBAZINE WITHOUT RADIATION IN NON‐BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMA7
PROSPECTIVE VALIDATION OF RECIL RESPONSE CRITERIA: RESULTS OF OBINUTUZUMAB‐GDP AS SALVAGE PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT IN AGGRESSIVE B CELL LYMPHOMA7
EPSTEIN‐BARR VIRUS‐DRIVEN DISEASES: A MULTINATIONAL, MULTICOHORT, OPEN‐LABEL PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF TABELECLEUCEL USING AN ADAPTIVE STUDY DESIGN7
A PHASE II STUDY OF ACALABRUTINIB IN COMBINATION WITH R‐CHOP CHEMOTHERAPY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA7
REAL WORLD OUTCOME IN MANTLE CELL LYMPHOMA: A FRENCH RETROSPECTIVE STUDY IN ELDERLY PATIENTS BETWEEN 2005 AND 20187
BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB, ACALABRUTINIB AND VENETOCLAX IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAAG TRIAL OF THE GCLLSG7
FRACTIONATED TOTAL‐BODY IRRADIATION AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS STEM‐CELL SUPPORT IN PATIENTS WITH T‐CELL LYMPHOBLASTIC LYMPHOMA7
PUBLICATION7
MTV, TLG AND SUV MAX AS PROMISING PARAMETERS TO PREDICT EARLY RESPONSE IN PATIENTS WITH HL TREATED WITH ABVD. A RETROSPECTIVE SUB‐ANALYSIS OF THE GATLA‐LH‐05 TRIAL7
A UK POPULATION‐BASED STUDY OF NON‐HODGKIN LYMPHOMA IN TEENAGERS AND YOUNG ADULTS (TYA) DELAYED DIAGNOSIS AND DEATH7
IMMUNE PRIMING WITH NIVOLUMAB FOLLOWED BY NIVOLUMAB & RITUXIMAB IN 1ST LINE TREATMENT OF FOLLICULAR LYMPHOMA: THE PHASE 2 1ST FLOR STUDY7
TARGETING PROXIMAL BCR SIGNALING PATHWAY IN DIFFUSE LARGE B‐CELL LYMPHOMA7
CYTIDINE DEAMINASES SHAPE THE GENOME OF GERMINAL CENTER B CELL DERIVED LYMPHOMA7
WHOLE GENOME SEQUENCING OF MATCHED PRIMARY AND RELAPSED DLBCL REVEALS DISTINCT EVOLUTIONARY DYNAMICS ASSOCIATED WITH RELAPSE TIMING7
OUTCOME OF PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA AFTER HIGH‐DOSE METHOTREXATE FOLLOWED BY CONSOLIDATION WHOLE‐BRAIN RADIOTHERAPY AND CYTARABINE7
A GENE SIGNATURE TO PREDICT RISK OF TRANSFORMATION IN PATIENTS WITH FOLLICULAR LYMPHOMA7
BASELINE METABOLIC TUMOR VOLUME AND IPS PREDICT ABVD FAILURE IN ADVANCED‐STAGE HODGKIN LYMPHOMA WITH A NEGATIVE INTERIM PET SCAN AFTER 2 CHEMOTHERAPY CYCLES. A RETROSPECTIVE ANALYSIS FROM THE GITIL/FI7
THE ROLE OF MULTIPARAMETRIC FLOW CYTOMETRY IN DETECTING AND CHARACTERIZING GAMMA‐DELTA T‐CELL ENTITIES IN PERIPHERAL BLOOD. SINGLE‐CENTER CASE SERIES AND LITERATURE REVIEW7
COMPARATIVE EVALUATION OF RADIATION THERAPY TECHNIQUES FOR MEDIASTINUM IRRADIATION IN LYMPHOMA PATIENTS USING IMRT, B‐VMAT, 3DCRT7
SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY)7
PROGNOSTIC ROLE OF LESION DISSEMINATION FEATURE (DMAX) CALCULATED ON BASELINE PET/CT IN HODGKIN LYMPHOMA6
High inter‐follicular spatial co‐localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma6
Pirarubicin‐based intensive chemotherapy followed by consolidative high‐dose chemotherapies for peripheral T‐cell lymphomas: A noncomparative phase 2 study6
A novel clinical immune‐related prognostic model predicts the overall survival of mantle cell lymphoma6
FIRST IN HUMAN STUDY OF AUTO4, A TRBC1‐TRAGETTING CART T CELL THERAPY IN RELAPSED/REFRACTORY TRBC1‐POSITIVE PERIPHERAL T‐CELL LYMPHOMA6
Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk‐adapted, response‐adapted, and safer than before6
EFFECTIVENESS OF THERAPY WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA6
PHASE IB/II STUDY OF LENALIDOMIDE, RITUXIMAB, HIGH‐DOSE METHOTREXATE (R2‐MTX) REGIMEN, FOLLOWED BY LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA6
R‐CODOX‐M/R‐IVAC IN HIGH RISK AND MYC MUTATED DIFFUSE LARGE B CELL LYMPHOMA‐ A SINGLE CENTRE RETROSPECTIVE STUDY6
Are we reaching the maximum cure rate for Hodgkin lymphoma?6
Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia6
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement6
Issue Information6
Heat shock protein 90 inhibitors induce cell differentiation via the ubiquitin‐dependent aurora kinase A degradation in a MPLW515L mouse model of primary myelofibrosis6
Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis6
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997–206
USE OF METHOTREXATE, WHATEVER KIDNEY FUNCTION, WITH A SIMPLE ALGORITHM, RADICALLY CHANGES THE PROGNOSIS OF POST‐TRANSPLANT CNS LYMPHOMAS6
CLINICAL UTILITY OF INTERIM CT SCANS IN PATIENTS RECEIVING CHEMOIMMUNOTHERAPY FOR FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA6
CLINICAL OUTCOMES OF RELAPSED HODGKIN LYMPHOMA PATIENTS AFTER CONTEMPORARY FIRST‐LINE TREATMENT: RESULTS FROM THE GERMAN HODGKIN STUDY GROUP6
How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B‐cell lymphoma?6
Long‐term follow‐up and health‐related quality of life among cancer survivors with stage IEA orbital‐type lymphoma after external photon‐beam radiotherapy: Results from a longitudinal study6
EARLY SAFETY AND EFFICACY DATA FROM A PHASE I/II TRIAL OF DZD4205, A SELECTIVE JAK1 INHIBITOR, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA6
6
Report of PRPF19 as a novel partner of RARG and the recurrence of interposition‐type fusion in variant acute promyelocytic leukemia6
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis6
6
PET‐ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH‐05 TRIAL6
CLADRIBINE AS FRONTLINE TREATMENT OF HAIRY CELL LEUKEMIA: A MULTICENTER EUROPEAN EXPERIENCE OF MORE THAN 30 YEARS ON 384 PATIENTS6
Prognostic impact of complex karyotype on post‐transplant outcomes of myelofibrosis5
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment for chronic lymphocytic leukemia/ small lymphocytic leukemia: a single‐arm study5
Proteomic profiling identifies apoptotic deregulation predictive of histological transformation in follicular lymphoma5
Role of autologous stem cell transplantation or salvage chemotherapy in relapsed/refractory classical Hodgkin lymphoma patients after immune checkpoint inhibitors5
Patient‐ versus clinician‐reported symptoms in the POLARIX study5
A 9‐LNCRNA SIGNATURE FOR PREDICTING PROGNOSIS AND IMMUNE RESPONSE IN DIFFUSE LARGE B‐CELL LYMPHOMA5
Proteomic profiling differentiates classic Hodgkin lymphoma with and without skeletal involvement at the time of diagnosis5
A five‐gene signature may associate with central nervous system dissemination in adult acute lymphoblastic leukemia5
Sinonasal B‐cell lymphomas: A nationwide cohort study, with an emphasis on the prognosis and the recurrence pattern of primary diffuse large B‐cell lymphoma5
Racial differences in the survival of mantle cell lymphoma patients in the United States5
Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma5
Hepatitis C virus‐associated indolent B‐cell lymphomas: A review on the role of the new direct antiviral agents therapy5
Molecular diagnostics and reporting in lymphoid malignancies: Current status and beyond5
SAKK 38/19: ASSESSING A CTDNA AND PET‐ORIENTED THERAPY IN PATIENTS WITH DLBCL. A MULTICENTER, OPEN‐LABEL, PHASE II TRIAL5
A single‐center experience of low‐dose radiotherapy for primary extranodal marginal zone lymphoma of bronchus‐associated lymphoid tissue (BALT)5
ONKOFRAIL: PERSONALIZATION OF A PHYSICAL EXERCISE PROGRAM IN OLDER PATIENTS WITH LYMPHOMA5
ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY5
Personalized monitoring of circulating tumor DNA by a specific signature of trackable mutations after chimeric antigen receptor t‐cell therapy in non‐Hodgkin B cell lymphoma5
Non‐overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia5
New drugs and pharmacological interactions in real life5
A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S00165
A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma—Outcomes indicative for improved survival overtime5
Efficacy and safety of PD‐1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study5
Issue Information5
INTEGRATING MULTI‐OMICS ANALYSIS AND ASPARAGINASE ACTIVITY CURVE TO EXPLAIN DRAMATIC PROGNOSIS DIFFERENCES BETWEEN EARLY AND ADVANCED‐STAGE IN ENKTL PATIENTS5
TRACES OF EPSTEIN BARR VIRUS (EBV) ARE NOT INVOLVED IN THE PATHOGENESIS OF DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)5
NX‐0255 AND NX‐1607, SMALL MOLECULE INHIBITORS OF CBL‐B, ARE EFFICACIOUS IN COMBINATION WITH ADOPTIVE CELL THERAPY OR RITUXIMAB IN PRECLINICAL MOUSE MODELS OF LYMPHOMA5
Activation of the Novel Tumor Suppressor SAMHD1 Inhibits Cell Growth and Induces Interferon‐beta (IFN‐β) Gene Expression in Classical Hodgkin Lymphoma (cHL)5
Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR)5
INCREASED SOLUBLE SERUM CD163 (SCD163) LEVELS PREDICT A SHORT DISEASE FREE SURVIVAL IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)5
Issue Information5
CHARACTERIZATION OF CANCER ASSOCIATED FIBROBLASTS IN CLASSICAL HODGKIN LYMPHOMA5
First external validation of the FLIPI‐L score in a single‐center series of patients with follicular lymphoma5
The course of patients with hairy cell leukemia during the omicron surge of the Covid‐19 pandemic5
Unmet clinical needs in the use of zanubrutinib in malignant lymphomas (Waldenström macroglobulinemia, marginal zone lymphoma and mantle cell lymphoma): A consensus‐based position paper from an ad hoc5
PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐54
Robust Bruton’s tyrosine kinase (BTK) degradation with NX‐5948, an oral BTK degrader, in a first‐in‐human phase 1a trial in relapsed/refractory B cell malignancies4
Long‐term outcomes with mogamulizumab alone or in combination with other therapies for the treatment of cutaneous t‐cell lymphoma4
Brentuxinmab vedotin, alone or combine with bendamustine in the treatment of natural killer T cell lymphoma4
New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model4
Diagnosis of chronic B‐cell lymphoproliferative disease in peripheral blood = how machine learning may help to the interpretation of flow cytometry data4
Reappraisal of the role of radiation therapy in lymphoma treatment4
GENETIC SUBTYPE GUIDED RITUXIMAB‐BASED IMMUNOCHEMOTHERAPY IMPROVES OUTCOME IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: FIRST REPORT OF A RANDOMIZED PHASE 2 STUDY4
A PHASE 2 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE (LONCA) VERSUS (VS) IDELALISIB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) – LOTIS‐64
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B‐Cell lymphoma ‐results of a single center, retrospective 4
TET2 regulates extranodal NK/T cell lymphoma progression through regulation of DNA methylation4
Ibrutinib combined with low‐dose histone deacetylases inhibitor chidamide synergistically enhances the anti‐tumor effect in B‐cell lymphoma4
Risk of a second cancer and infection in patients with indolent B‐cell lymphoma exposed to first‐line bendamustine plus rituximab: A retrospective analysis of an administrative claims database4
NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY4
THE RNA M6A READER YTHDF2 REGULATES ACER2‐CERAMIDE METABOLIC AXIS TO PROMOTE TUMORIGENESIS OF DIFFUSE LARGE B‐CELL LYMPHOMA4
Secondary cancer is the leading cause of death 15 years or more after diagnosis of early‐stage Hodgkin lymphoma4
Long‐term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients4
A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non‐Hodgkin lymphoma4
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study4
AN OPEN‐LABEL TRIAL OF ORAL CA‐4948 AN IRAK4 INHIBITOR COMBINED WITH IBRUTINIB IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES4
CAR‐HEMATOTOX: A DISCRIMINATIVE MODEL FOR CAR T‐CELL RELATED HEMATOTOXICITY IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA4
Novel agents in relapsed/refractory diffuse large B‐cell lymphoma4
Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta‐analysis of randomized clinical trials4
Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial4
Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions4
4
[18F]‐FDG PET radiomic model as prognostic biomarker in diffuse large B‐cell lymphoma4
CLINICAL FEATURES AND PROGNOSIS OF PATIENTS COEXISTING WITH FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B‐CELL LYMPHOMA: A RETROSPECTIVE OBSERVATIONAL STUDY4
Safety of acalabrutinib treatment in very old (≥80 y) and/or frail patients with chronic lymphocytic leukemia ‐ interim safety analysis of the ongoing phase II CLL‐Frail trial4
Treatment‐related toxicity disparities in adult Hispanic acute lymphoblastic leukemia patients receiving pegaspargase‐based regimens: A multicenter electronic health research network study4
PILOT PHASE II STUDY OF SELINEXOR IN COMBINATION WITH IFOSFAMIDE, ETOPOSIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMAS (R/R PTCLS)4
Liposomal‐encapsulated doxorubicin supercharge‐containing front‐line treatment improves response rates in primary mediastinal large B‐cell lymphoma and mediastinal gray zone lymphoma4
PERVASIVE HYPERMUTATION OF SUPER‐ENHANCER REGIONS DYSREGULATES ONCOGENE EXPRESSION IN DIFFUSE LARGE B‐CELL LYMPHOMA4
LncRNA FEZF1‐AS1 accelerates multiple myeloma progression by regulating IGF2BP1/BZW2 signaling4
Pre‐treatment health‐related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA‐BERIT) experienc4
Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma4
Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4‐positive peripheral T‐cell lymphoma and relapsed or refractory cutaneous T‐cell lymphoma: A post‐marketing s4
Primary testicular lymphoma demonstrates overexpression of the Wilms tumor 1 gene and different mRNA and miRNA expression profiles compared to nodal diffuse large B‐cell lymphoma4
Molecular remission is an independent predictor of progression‐free survival in patients with Waldenström macroglobulinemia treated with chemo‐immunotherapy: Results from the FIL_BIOWM study4
Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry3
ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA: FINAL ANALYSIS OF THE RO‐CHOP TRIAL3
Deciphering the role of macrophages and T cells in primary central nervous system lymphoma: tumour aggressiveness and response to immunotherapies3
ENHANCER RNAS (ERNAS) PLAY A ROLE IN THE RESPONSE TO SMALL MOLECULES AND IN THE DEVELOPMENT OF ACQUIRED RESISTANCE IN MARGINAL ZONE LYMPHOMA (MZL)3
Next Generation Sequencing in routine diagnostics of mature non‐Hodgkin’s lymphomas. A single‐center real‐life data study3
Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma3
Trends in relative survival of Diffuse large B‐cell lymphoma in Sweden in the era of targeted and cellular therapies3
Improved method to stratify lymphoma patients with risk of secondary central nervous system involvement: A multicenter retrospective analysis3
Host‐related factors and cancer: Malnutrition and non‐Hodgkin lymphoma3
Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax3
What's new in peripheral T‐cell lymphomas3
Successful early treatment combining remdesivir with high‐titer convalescent plasma among COVID‐19‐infected hematological patients3
NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S18263
Langerhans cell histiocytosis: Version 20213
The treatment of Burkitt lymphoma with the Berlin‐Frankfurt‐Münster protocol with rituximab and autologous transplantation3
Circ_0009910 shuttled by exosomes regulates proliferation, cell cycle and apoptosis of acute myeloid leukemia cells by regulating miR‐5195‐3p/GRB10 axis3
Brentuximab Vedotin‐Nivolumab alone and then with Rituximab‐Cyclophosphamide‐Doxorubicin‐Prednisone as Frontline Therapy of Primary Mediastinal Large B‐cell Lymphoma3
Long term outcomes of gastric mucosa‐associated lymphoid tissue lymphoma treated with radiotherapy: A multi‐center retrospective cohort study3
Responses after Allogeneic NK Cell Therapy for Lymphoma: correlative analysis revealed impact of host monocytes and robust T cells tumor trafficking3
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia3
DYNAMICS OF RADIOMIC FEATURES FOLLOWING BRIDGING THERAPY DETERMINE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY OUTCOME3
Real‐world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience3
A comprehensive analysis of coagulopathy during anti‐B cell maturation antigen chimeric antigen receptor‐T therapy in multiple myeloma, a retrospective study based on LEGEND‐23
Real‐life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B‐cell lymphomas3
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia3
Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia3
OUTCOMES IN ELDERLY HODGKIN LYMPHOMA: RESULTS FROM KOREAN MULTICENTER COHORT3
REAL WORLD EXPERIENCE OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN A MULTI‐ETHNIC ASIAN COHORT3
Analyses of a patient with 3 sequential Post Transplant Lymphoprolierative Disease (PTLD) biopsies reveal persistence of Histone 1 gene mutation, suspected to mediate PTLD3
B‐cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non‐Hodgkin's Lymphoma3
THE TUMOR MICROENVIRONMENT OF HODGKIN LYMPHOMA AT SINGLE CELL RESOLUTION3
Classic Hodgkin lymphoma3
CLINICOPATHOLOGICAL CHARACTERISTICS OF PATIENTS WITH NON‐HODGKIN LYMPHOMA OF THE OCULAR ADNEXA3
Allogeneic transplantation for adult T‐cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for tran3
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐3
Efficacy and follow‐up of humanized anti‐BCMA CAR‐T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary‐extraosseous, extramedullary‐bone related, and without extramedull3
Bruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials3
Malnutrition diagnosed by GLIM criteria better predicts long‐term outcomes for patients with non‐Hodgkin's lymphoma: A prospective multicenter cohort study3
LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): PRIMARY ANALYSIS OF TRANSCEND CLL 0043
Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study3
0.21093392372131